scholarly journals Molecular targeted agents as second-line treatment for hepatocellular carcinoma: a meta-analysis and review

Oncotarget ◽  
2017 ◽  
Vol 8 (60) ◽  
pp. 102321-102327 ◽  
Author(s):  
Jung Han Kim ◽  
Bum Jun Kim ◽  
Hyun Joo Jang ◽  
Jin Lee
Keyword(s):  
Hepatocellular Carcinoma ◽  
Meta Analysis ◽  
Line Treatment ◽  
Second Line ◽  
Targeted Agents ◽  
Molecular Targeted Agents

scholarly journals Targeted agents for second-line treatment of advanced hepatocellular carcinoma

2019 ◽  
Vol 11 (10) ◽  
pp. 788-803 ◽  
Author(s):  
Nicola Personeni ◽  
Tiziana Pressiani ◽  
Silvia Bozzarelli ◽  
Lorenza Rimassa
Keyword(s):  
Hepatocellular Carcinoma ◽  
Advanced Hepatocellular Carcinoma ◽  
Line Treatment ◽  
Second Line ◽  
Targeted Agents

scholarly journals Second-line treatment in patients with pancreatic ductal adenocarcinoma: A meta-analysis

Cancer ◽  
2017 ◽  
Vol 123 (23) ◽  
pp. 4680-4686 ◽  
Author(s):  
Mohamad Bassam Sonbol ◽  
Belal Firwana ◽  
Zhen Wang ◽  
Diana Almader-Douglas ◽  
Mitesh J. Borad ◽  
...  
Keyword(s):  
Pancreatic Ductal Adenocarcinoma ◽  
Meta Analysis ◽  
Ductal Adenocarcinoma ◽  
Line Treatment ◽  
Second Line

scholarly journals MicroRNA-3163 targets ADAM-17 and enhances the sensitivity of hepatocellular carcinoma cells to molecular targeted agents

2019 ◽  
Vol 10 (10) ◽  
Author(s):  
Bin Yang ◽  
Chunping Wang ◽  
Hui Xie ◽  
Yiwu Wang ◽  
Jiagan Huang ◽  
...  
Keyword(s):  
Hepatocellular Carcinoma ◽  
Notch Signaling ◽  
Signaling Pathway ◽  
Epithelial Mesenchymal Transition ◽  
Notch Signaling Pathway ◽  
Advanced Hepatocellular Carcinoma ◽  
Targeted Agents ◽  
Mesenchymal Transition ◽  
Molecular Targeted Agents ◽  
Hcc Cells

Abstract Molecular targeted agents, such as sorafenib, remain the only choice of an antitumor drug for the treatment of advanced hepatocellular carcinoma (HCC). The Notch signaling pathway plays central roles in regulating the cellular injury/stress response, anti-apoptosis, or epithelial–mesenchymal transition process in HCC cells, and is a promising target for enhancing the sensitivity of HCC cells to antitumor agents. The ADAM metalloprotease domain-17 (ADAM-17) mediates the cleavage and activation of Notch protein. In the present study, microRNA-3163 (miR-3163), which binds to the 3′-untranslated region of ADAM-17, was screened using online methods. miRDB and pre-miR-3163 sequences were prepared into lentivirus particles to infect HCC cells. miR-3163 targeted ADAM-17 and inhibited the activation of the Notch signaling pathway. Infection of HCC cells with miR-3163 enhanced their sensitivity to molecular targeted agents, such as sorafenib. Therefore, miR-3163 may contribute to the development of more effective strategies for the treatment of advanced HCC.

Sign in / Sign up

Export Citation Format

Share Document